TEZSPIRE met both co-primary endpoints in the Phase III …
Nov 8, 2024 · TEZSPIRE ® (tezepelumab-ekko) INDICATION TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. CONTRAINDICATIONS Known hypersensitivity to tezepelumab-ekko or excipients.
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL …
Nov 8, 2024 · TEZSPIRE ® (tezepelumab ... This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of ...
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal …
6 days ago · The news comes on the heels of mixed Phase IIb data for Tezspire in chronic obstructive pulmonary disease (COPD). The therapy failed to meet the primary endpoint of the placebo-controlled Phase IIa COURSE trial (NCT04039113). However, in a pre-determined subgroup analysis of COPD patients based on the levels of eosinophils, Tezspire showed a 48% reduction in severe exacerbations compared to ...
Positive high-level results from the Phase III WAYPOINT trial of ...
Nov 8, 2024 · Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo
FDA approves maintenance treatment for severe asthma
Dec 20, 2021 · FDA has approved Tezspire (tezepelumab-ekko) injection as an add-on maintenance treatment used to improve severe asthma symptoms when used with a patient’s current asthma medicine.
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR ... - Amgen
Dec 17, 2021 · Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine. 3 It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase 2 and 3 clinical trials, which included a broad ...
NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ …
THOUSAND OAKS, Calif., Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ (tezepelumab-ekko) demonstrated reductions in the annualized asthma exacerbation rate (AAER) across biomarker subgroups of patients with ...
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
Dec 17, 2021 · TEZSPIRE™ (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial ...
Tezspire (tezepelumab) approved in the US for severe asthma - AstraZeneca
Dec 17, 2021 · Tezspire (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL …
6 days ago · TEZSPIRE is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults.
- Some results have been removed